▲ +107.94% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Aldeyra Therapeutics in the last 3 months. The average price target is $25.56, with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 107.94% upside from the last price of $12.29.
The current consensus among 9 polled investment analysts is to buy stock in Aldeyra Therapeutics. This Buy consensus rating has held steady for over two years.
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.